Skip to main content

Advertisement

SpringerLink
Log in

Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Median age at diagnosis for patients with chronic lymphocytic leukemia (CLL) is 72 years, and the number of older individuals affected by this condition is predicted to increase in the future as populations age. Contrary to common assumptions, CLL significantly affects the life expectancy of older individuals, frequently presenting at a more advanced stage and with more unfavorable features than in the younger population. Therefore, identifying the optimal treatment for these patients is a priority. Older patients with CLL are usually classified as fit, non-fit, or frail based on performance status and comorbidities, and several assessment tools can be used to make these evaluations. While supportive care is appropriate for frail patients, the remaining patients should be treated when indication criteria are met. Treatment options include chemoimmunotherapy, monoclonal antibody-based approaches (such as the use of rituximab, ofatumumab, or obinutuzumab) and, more recently, small molecules (such as ibrutinib, idelalisib, and venetoclax). The choice of treatment is guided by the patient’s performance status and co-morbidities and by the disease characteristics, such as chromosomal and molecular abnormalities, and in patients with recurrent disease also by the type of prior regimen, their tolerability, and duration of response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Cancer Institute. Cancer stat facts: leukemia—chronic lymphocytic leukemia (CLL). http://seer.cancer.gov/statfacts/html/clyl.html. Accessed 20 Apr 2019.

  2. http://populationpyramid.net.html.

  3. Pulte D, Redaniel MT, Bird J, Jeffreys M. Survival for patients with chronic leukemias in the US and Britain: age-related disparities and changes in the early 21st century. Eur J Haematol. 2015;94(6):540–5.

    Article  PubMed  Google Scholar 

  4. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, et al. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010;116(20):4777–87.

    Article  PubMed  Google Scholar 

  5. Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178(3):394–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ferrajoli AOBS, Lerner S, Wierda W, Faderl S, Keating MJ. Chronic lymphocytic leukemia in the elderly, outcome of patients age 70 and older. Leuk Lymphoma. 2003;44(Suppl 2):S1–56.

    Google Scholar 

  7. Baumann T, Delgado J, Santacruz R, Martinez-Trillos A, Royo C, Navarro A, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica. 2014;99(10):1599–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Truger MS, Jeromin S, Weissmann S, Dicker F, Kern W, Schnittger S, et al. Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia. Br J Haematol. 2015;168(1):153–6.

    Article  PubMed  Google Scholar 

  9. International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–90.

    Article  Google Scholar 

  10. Molica S, Giannarelli D, Mirabelli R, Levato L, Kay NE, Shanafelt TD. Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood. 2018;131(3):365–8.

    Article  CAS  PubMed  Google Scholar 

  11. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.

    Article  CAS  PubMed  Google Scholar 

  12. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49–56.

    Article  PubMed  Google Scholar 

  13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.

    Article  CAS  PubMed  Google Scholar 

  14. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46(4):M139–44.

    Article  CAS  PubMed  Google Scholar 

  15. Vojdeman FJ, Van’t Veer MB, Tjonnfjord GE, Itala-Remes M, Kimby E, Polliack A, et al. The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58(3):594–600.

    Article  CAS  PubMed  Google Scholar 

  16. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–15.

    Article  CAS  PubMed  Google Scholar 

  17. Eketorp Sylvan S, Lundin J, Ipek M, Palma M, Karlsson C, Hansson L. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol. 2014;93(10):1725–33.

    Article  CAS  PubMed  Google Scholar 

  18. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3):237–48.

    Article  CAS  PubMed  Google Scholar 

  19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

    Article  CAS  PubMed  Google Scholar 

  20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  CAS  PubMed  Google Scholar 

  21. National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.

    Google Scholar 

  22. Michallet AS, Cazin B, Bouvet E, Oberic L, Schlaifer D, Mosser L, et al. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis. J Geriatr Oncol. 2013;4(2):141–7.

    Article  PubMed  Google Scholar 

  23. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Goede V, Bahlo J, Chataline V, Eichhorst B, Durig J, Stilgenbauer S, et al. Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group. Leuk Lymphoma. 2016;57(4):789–96.

    Article  CAS  PubMed  Google Scholar 

  25. Welsh TJ, Gordon AL, Gladman JR. Comprehensive geriatric assessment—a guide for the non-specialist. Int J Clin Pract. 2014;68(3):290–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gribben JG. Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther. 2010;10(9):1389–94.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Osterborg A, et al. Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. Ann Oncol. 2017;28(2):218–27.

    CAS  PubMed  Google Scholar 

  28. Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematol Am Soc Hematol Educ Progr. 2013;2013:158–67.

    Article  Google Scholar 

  29. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer. 2013;119(21):3805–11.

    Article  CAS  PubMed  Google Scholar 

  32. Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209–16.

    Article  CAS  PubMed  Google Scholar 

  33. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42.

    Article  CAS  PubMed  Google Scholar 

  34. Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol. 2014;32(12):1236–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Strati P, Tong WG, Vitale C, Wierda WG, O’Brien S, Brown JR, et al. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(6):1878–80.

    Article  PubMed  Google Scholar 

  36. Foa R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014;89(5):480–6.

    Article  CAS  PubMed  Google Scholar 

  37. Flinn IW, Ruppert AS, Harwin W, Waterhouse D, Papish S, Jones JA, et al. A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia. Am J Hematol. 2016;91(10):1020–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vitale C, Ciccone M, Hinojosa C, Keating M, Pemmaraju N, O’Brien S, et al. Front-line treatment with ofatumumab for older unfit patients with chronic lymphocytic leukemia. Blood. 2015;126:23.

    Article  Google Scholar 

  39. Goede V FK, Dyer MJS, Müller L, Smolej L, Di Bernardo MC et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analaysis of the CLL11 Study. EHA. 2018.

  40. Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873–83.

    Article  CAS  PubMed  Google Scholar 

  41. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124(10):1637–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin N Am. 2013;27(2):207–35.

    Article  Google Scholar 

  44. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O’Brien SM, et al. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia. 2018;32(10):2278–81.

    Article  CAS  PubMed  Google Scholar 

  46. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122(5):734–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Strati P, Thompson PA, Keating M, Hinojosa C, Rodriguez D, Wang XM, et al. A Phase II study of the combination of lenalidomide and rituximab in patients with treatment-NaiVe and relapsed chronic lymphocytic leukemia. Blood. 2016;128:22.

    Article  Google Scholar 

  48. Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, et al. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia. 2017;31(5):1240–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Zelenetz AD, Lamanna N, Kipps TJ, Coutre SE, O’Brien S, Aiello M, et al. A phase 2 study of idelalisib monotherapy in previously untreated patients > = 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood. 2014;124:21.

    Article  Google Scholar 

  50. O’Brien S, Lamanna N, Kipps TJ, Flinn IW, Zelenetz AD, Burger JA, et al. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-Naive patients > = 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood. 2014;124:21.

    Article  Google Scholar 

  51. O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126(25):2686–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131(17):1910–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–76.

    Article  CAS  PubMed  Google Scholar 

  55. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett NL, et al. Updated efficacy and safety from the phase 3 resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood. 2016;128(22):234.

    Article  Google Scholar 

  58. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.

    Article  CAS  PubMed  Google Scholar 

  60. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, Coutre S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab. Blood. 2019.

  63. Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138–40.

    Article  CAS  PubMed  Google Scholar 

  65. Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, et al. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017;58(6):1376–83.

    Article  CAS  PubMed  Google Scholar 

  66. Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, et al. The impact of atrial fibrillation on subsequent survival of patients receiving ibrutinib as treatment of chronic lymphocytic leukemia (CLL): an international study. Blood. 2016;128:22.

    Article  CAS  Google Scholar 

  67. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–8.

    Article  CAS  PubMed  Google Scholar 

  69. Coutre S, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, et al. Integrated and long-term safety analysis of ibrutinib in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Blood. 2016;128:22.

    Article  Google Scholar 

  70. Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Ysebaert L, Levade M, Cedric G, Michallet AS, Tam C, Pierre S, et al. Elucidation of mild bleeding disorders reported under ibrutinib (Imbruvica(R)) therapy: implications for optimal clinical management. Blood. 2014;124:21.

    Article  Google Scholar 

  72. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32.

    Article  CAS  PubMed  Google Scholar 

  73. Hillmen P, Brown JR, Kahl BS, Ghia P, Robak T, Marimpietri C. Phase 3 zanubrutinib (BGB-3111) vs bendamustine plus rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). J Clin Oncol. 2018;36:15.

    Article  Google Scholar 

  74. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.

    Article  CAS  PubMed  Google Scholar 

  75. Jain N, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, et al. Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed/refractory CLL: a phase II trial. Blood. 2017;130(Suppl 1):429.

    Google Scholar 

  76. Hillmen P, Munir T, Rawstron A, Brock K, Munoz Vicente S, Yates F, et al. Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. Blood. 2017;130(Suppl 1):428.

    Google Scholar 

  77. Fischer K, Al-Sawaf O, Fink A-M, Dixon M, Bahlo J, Warburton S, et al. Safety and efficacy of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions: final results of the run-in phase of the randomized CLL14 trial (BO25323). Blood. 2016;128(22):2054.

    Article  Google Scholar 

  78. Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Paolo Strati

  2. Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Alessandra Ferrajoli

Authors
  1. Paolo Strati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Ferrajoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandra Ferrajoli.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Dr. Paolo Strati and Dr. Alessandra Ferrajoli declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strati, P., Ferrajoli, A. Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. Drugs Aging 36, 841–851 (2019). https://doi.org/10.1007/s40266-019-00678-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-019-00678-5

Search

Navigation